Ahmed Sallam
Concepts (375)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Vitrectomy | 30 | 2024 | 58 | 9.780 |
Why?
| Cataract | 14 | 2024 | 45 | 7.590 |
Why?
| Visual Acuity | 36 | 2024 | 138 | 7.560 |
Why?
| Macular Edema | 16 | 2024 | 27 | 6.900 |
Why?
| Phacoemulsification | 15 | 2024 | 31 | 6.340 |
Why?
| Cataract Extraction | 14 | 2024 | 32 | 5.620 |
Why?
| Retinal Detachment | 14 | 2024 | 24 | 4.940 |
Why?
| Diabetic Retinopathy | 10 | 2024 | 40 | 4.860 |
Why?
| Intraoperative Complications | 15 | 2024 | 112 | 4.790 |
Why?
| Tomography, Optical Coherence | 19 | 2024 | 102 | 4.280 |
Why?
| Uveitis | 12 | 2024 | 29 | 4.110 |
Why?
| Ophthalmology | 8 | 2023 | 31 | 3.910 |
Why?
| Glaucoma | 8 | 2024 | 34 | 3.680 |
Why?
| Endophthalmitis | 11 | 2023 | 25 | 3.390 |
Why?
| Epiretinal Membrane | 5 | 2024 | 10 | 3.380 |
Why?
| Glucocorticoids | 15 | 2023 | 226 | 3.270 |
Why?
| Eye Infections, Bacterial | 8 | 2024 | 31 | 2.930 |
Why?
| Dexamethasone | 9 | 2023 | 430 | 2.790 |
Why?
| Postoperative Complications | 15 | 2024 | 996 | 2.770 |
Why?
| Retrospective Studies | 51 | 2024 | 6134 | 2.680 |
Why?
| Drug Implants | 9 | 2023 | 35 | 2.550 |
Why?
| Triticum | 4 | 2023 | 7 | 2.520 |
Why?
| Humans | 123 | 2024 | 50208 | 2.360 |
Why?
| Fluorescein Angiography | 7 | 2024 | 32 | 2.310 |
Why?
| Syphilis | 5 | 2024 | 27 | 2.300 |
Why?
| Comprehension | 5 | 2024 | 110 | 2.290 |
Why?
| Lens Implantation, Intraocular | 8 | 2024 | 22 | 2.170 |
Why?
| Hordeum | 3 | 2022 | 5 | 2.170 |
Why?
| Vitreoretinal Surgery | 5 | 2024 | 8 | 2.160 |
Why?
| Intraocular Pressure | 10 | 2024 | 55 | 2.080 |
Why?
| Diabetes Mellitus | 4 | 2022 | 286 | 2.030 |
Why?
| Eye Infections, Fungal | 6 | 2021 | 19 | 1.970 |
Why?
| Retinal Vessels | 3 | 2024 | 14 | 1.970 |
Why?
| Retinal Vein Occlusion | 6 | 2023 | 14 | 1.950 |
Why?
| Papilledema | 4 | 2022 | 27 | 1.930 |
Why?
| Retinitis Pigmentosa | 2 | 2024 | 7 | 1.850 |
Why?
| Fluorocarbons | 3 | 2023 | 45 | 1.540 |
Why?
| Angiogenesis Inhibitors | 7 | 2022 | 188 | 1.490 |
Why?
| Fibrin | 2 | 2023 | 10 | 1.470 |
Why?
| Retinal Diseases | 7 | 2021 | 50 | 1.460 |
Why?
| Paracentesis | 2 | 2023 | 13 | 1.450 |
Why?
| Intravitreal Injections | 15 | 2023 | 35 | 1.450 |
Why?
| Aged | 38 | 2024 | 9405 | 1.420 |
Why?
| Middle Aged | 41 | 2024 | 12206 | 1.410 |
Why?
| Databases, Factual | 10 | 2024 | 657 | 1.410 |
Why?
| Sclera | 2 | 2024 | 5 | 1.400 |
Why?
| Male | 58 | 2024 | 25399 | 1.380 |
Why?
| Tissue Plasminogen Activator | 2 | 2023 | 109 | 1.360 |
Why?
| Aged, 80 and over | 23 | 2024 | 3154 | 1.340 |
Why?
| Lenses, Intraocular | 2 | 2022 | 7 | 1.300 |
Why?
| Macular Degeneration | 4 | 2024 | 47 | 1.290 |
Why?
| Retinal Perforations | 4 | 2023 | 8 | 1.240 |
Why?
| Female | 55 | 2024 | 26635 | 1.210 |
Why?
| Choroid | 5 | 2024 | 24 | 1.200 |
Why?
| Fractals | 2 | 2024 | 8 | 1.190 |
Why?
| Retina | 7 | 2024 | 65 | 1.190 |
Why?
| Iris Diseases | 3 | 2020 | 4 | 1.160 |
Why?
| Wet Macular Degeneration | 3 | 2022 | 12 | 1.140 |
Why?
| Candidiasis | 3 | 2021 | 114 | 1.110 |
Why?
| Eye Injuries | 4 | 2024 | 27 | 1.070 |
Why?
| Societies, Medical | 3 | 2019 | 177 | 1.070 |
Why?
| Adult | 29 | 2024 | 13324 | 0.990 |
Why?
| Retinitis | 2 | 2022 | 5 | 0.970 |
Why?
| Internet | 2 | 2024 | 258 | 0.970 |
Why?
| Endotamponade | 4 | 2018 | 8 | 0.960 |
Why?
| Lighting | 1 | 2024 | 5 | 0.940 |
Why?
| Ciliary Body | 1 | 2024 | 4 | 0.930 |
Why?
| Anterior Chamber | 1 | 2023 | 8 | 0.920 |
Why?
| Lens, Crystalline | 1 | 2024 | 20 | 0.910 |
Why?
| Laser Coagulation | 1 | 2024 | 26 | 0.910 |
Why?
| Ocular Hypertension | 2 | 2016 | 6 | 0.910 |
Why?
| Triamcinolone Acetonide | 5 | 2011 | 15 | 0.900 |
Why?
| Panuveitis | 2 | 2021 | 6 | 0.900 |
Why?
| Anesthesia, General | 3 | 2024 | 91 | 0.900 |
Why?
| Germination | 1 | 2023 | 5 | 0.870 |
Why?
| Endoscopy | 1 | 2024 | 124 | 0.860 |
Why?
| Occlusive Dressings | 1 | 2022 | 6 | 0.850 |
Why?
| Artificial Intelligence | 1 | 2023 | 82 | 0.840 |
Why?
| State Medicine | 5 | 2023 | 14 | 0.840 |
Why?
| HIV Seropositivity | 1 | 2022 | 27 | 0.830 |
Why?
| Rift Valley Fever | 1 | 2022 | 1 | 0.830 |
Why?
| Antihypertensive Agents | 2 | 2016 | 121 | 0.820 |
Why?
| Optic Neuropathy, Ischemic | 1 | 2022 | 8 | 0.820 |
Why?
| Eye Foreign Bodies | 1 | 2022 | 7 | 0.810 |
Why?
| Enbucrilate | 1 | 2021 | 6 | 0.810 |
Why?
| Tissue Adhesives | 1 | 2021 | 13 | 0.800 |
Why?
| Reproducibility of Results | 7 | 2024 | 1185 | 0.780 |
Why?
| Stress, Physiological | 2 | 2019 | 170 | 0.770 |
Why?
| Varicose Veins | 2 | 2019 | 19 | 0.760 |
Why?
| Droughts | 4 | 2023 | 8 | 0.760 |
Why?
| Follow-Up Studies | 11 | 2024 | 2190 | 0.760 |
Why?
| Candida | 4 | 2020 | 60 | 0.740 |
Why?
| Choroiditis | 1 | 2020 | 9 | 0.740 |
Why?
| Child | 16 | 2024 | 6851 | 0.740 |
Why?
| Treatment Outcome | 15 | 2024 | 5155 | 0.730 |
Why?
| Retinal Vein | 2 | 2019 | 2 | 0.700 |
Why?
| Eye Diseases | 3 | 2024 | 38 | 0.690 |
Why?
| Photography | 4 | 2013 | 32 | 0.690 |
Why?
| Eyeglasses | 1 | 2019 | 9 | 0.690 |
Why?
| Crohn Disease | 1 | 2020 | 90 | 0.690 |
Why?
| Surgical Instruments | 1 | 2019 | 28 | 0.680 |
Why?
| Trichoderma | 1 | 2019 | 1 | 0.680 |
Why?
| Plant Diseases | 1 | 2019 | 8 | 0.680 |
Why?
| Pseudophakia | 5 | 2023 | 11 | 0.680 |
Why?
| Suture Techniques | 2 | 2022 | 59 | 0.660 |
Why?
| Fovea Centralis | 1 | 2018 | 5 | 0.640 |
Why?
| Laser Therapy | 1 | 2019 | 84 | 0.640 |
Why?
| Basement Membrane | 1 | 2018 | 18 | 0.640 |
Why?
| Imaging, Three-Dimensional | 1 | 2019 | 153 | 0.630 |
Why?
| HIV Infections | 1 | 2022 | 357 | 0.630 |
Why?
| National Health Programs | 2 | 2015 | 18 | 0.620 |
Why?
| Vascular Endothelial Growth Factor A | 5 | 2022 | 202 | 0.620 |
Why?
| Incidence | 11 | 2024 | 1006 | 0.600 |
Why?
| Fluocinolone Acetonide | 1 | 2017 | 5 | 0.600 |
Why?
| Egypt | 4 | 2022 | 13 | 0.600 |
Why?
| Air | 2 | 2016 | 23 | 0.580 |
Why?
| Prospective Studies | 8 | 2024 | 2379 | 0.570 |
Why?
| Minerals | 1 | 2016 | 30 | 0.550 |
Why?
| Sodium Chloride | 1 | 2016 | 58 | 0.540 |
Why?
| Chorioretinitis | 3 | 2024 | 9 | 0.540 |
Why?
| Vitreous Detachment | 1 | 2016 | 1 | 0.540 |
Why?
| Acetates | 1 | 2016 | 49 | 0.540 |
Why?
| Dissection | 1 | 2016 | 14 | 0.530 |
Why?
| Ophthalmologic Surgical Procedures | 1 | 2016 | 21 | 0.520 |
Why?
| Registries | 2 | 2018 | 522 | 0.520 |
Why?
| Anesthesia, Local | 1 | 2015 | 15 | 0.510 |
Why?
| Adrenergic alpha-1 Receptor Antagonists | 2 | 2020 | 8 | 0.500 |
Why?
| Child, Preschool | 10 | 2024 | 3883 | 0.490 |
Why?
| Cross-Sectional Studies | 6 | 2024 | 1554 | 0.480 |
Why?
| Microvessels | 2 | 2024 | 31 | 0.470 |
Why?
| Device Removal | 1 | 2014 | 85 | 0.440 |
Why?
| Treponema pallidum | 3 | 2024 | 10 | 0.440 |
Why?
| Iris | 3 | 2022 | 5 | 0.430 |
Why?
| Patient Education as Topic | 3 | 2024 | 313 | 0.420 |
Why?
| Vitreous Body | 5 | 2020 | 19 | 0.400 |
Why?
| Physical Examination | 2 | 2013 | 90 | 0.400 |
Why?
| Scleral Buckling | 3 | 2023 | 4 | 0.390 |
Why?
| Optic Disk | 2 | 2021 | 21 | 0.390 |
Why?
| Mydriatics | 1 | 2011 | 12 | 0.390 |
Why?
| Microscopy | 1 | 2011 | 57 | 0.380 |
Why?
| Seasons | 2 | 2022 | 82 | 0.360 |
Why?
| Vision Disorders | 4 | 2022 | 57 | 0.360 |
Why?
| Diagnostic Techniques, Ophthalmological | 2 | 2023 | 11 | 0.350 |
Why?
| Genotype | 2 | 2023 | 534 | 0.340 |
Why?
| Anti-Bacterial Agents | 5 | 2024 | 747 | 0.340 |
Why?
| Fibrinolytic Agents | 2 | 2023 | 125 | 0.340 |
Why?
| Intraoperative Period | 2 | 2019 | 45 | 0.340 |
Why?
| Vision, Low | 2 | 2022 | 9 | 0.340 |
Why?
| Fundus Oculi | 3 | 2024 | 25 | 0.330 |
Why?
| Lens Capsule, Crystalline | 2 | 2016 | 2 | 0.330 |
Why?
| Tonometry, Ocular | 2 | 2024 | 5 | 0.320 |
Why?
| Adrenergic alpha-Antagonists | 1 | 2008 | 27 | 0.320 |
Why?
| United States | 7 | 2024 | 4874 | 0.310 |
Why?
| Silicone Oils | 3 | 2023 | 3 | 0.310 |
Why?
| Eye Infections, Viral | 1 | 2008 | 2 | 0.310 |
Why?
| Ocular Hypotension | 1 | 2008 | 2 | 0.310 |
Why?
| Eye Infections, Parasitic | 1 | 2008 | 2 | 0.310 |
Why?
| Choroid Neoplasms | 1 | 2007 | 6 | 0.300 |
Why?
| Suction | 1 | 2008 | 24 | 0.300 |
Why?
| Phenotype | 2 | 2022 | 733 | 0.300 |
Why?
| Physicians, Family | 1 | 2008 | 64 | 0.300 |
Why?
| Eye Burns | 1 | 2007 | 1 | 0.290 |
Why?
| Ophthalmic Solutions | 1 | 2007 | 19 | 0.290 |
Why?
| Sulfonamides | 1 | 2008 | 128 | 0.290 |
Why?
| Hyaluronic Acid | 1 | 2007 | 34 | 0.290 |
Why?
| Anti-Infective Agents | 1 | 2008 | 95 | 0.280 |
Why?
| Adolescent | 9 | 2024 | 6390 | 0.280 |
Why?
| Vaccination | 3 | 2024 | 271 | 0.270 |
Why?
| Young Adult | 8 | 2024 | 3981 | 0.260 |
Why?
| Trabeculectomy | 1 | 2024 | 10 | 0.240 |
Why?
| Glaucoma Drainage Implants | 1 | 2024 | 6 | 0.240 |
Why?
| Cohort Studies | 2 | 2022 | 1422 | 0.240 |
Why?
| Vitreoretinopathy, Proliferative | 1 | 2024 | 2 | 0.240 |
Why?
| Syphilis Serodiagnosis | 1 | 2024 | 4 | 0.240 |
Why?
| Risk Factors | 8 | 2024 | 3629 | 0.230 |
Why?
| Garlic | 1 | 2024 | 5 | 0.230 |
Why?
| Proanthocyanidins | 1 | 2024 | 4 | 0.230 |
Why?
| Ciliary Arteries | 1 | 2024 | 3 | 0.230 |
Why?
| Abducens Nerve Diseases | 1 | 2024 | 8 | 0.230 |
Why?
| Burns, Chemical | 1 | 2024 | 9 | 0.230 |
Why?
| Melanoma | 1 | 2007 | 290 | 0.230 |
Why?
| Search Engine | 1 | 2023 | 7 | 0.230 |
Why?
| Health Knowledge, Attitudes, Practice | 1 | 2008 | 486 | 0.230 |
Why?
| Consumer Health Information | 1 | 2023 | 16 | 0.230 |
Why?
| Glaucoma, Open-Angle | 1 | 2024 | 21 | 0.230 |
Why?
| Inflammation | 3 | 2022 | 604 | 0.230 |
Why?
| Tattooing | 1 | 2023 | 5 | 0.220 |
Why?
| Sex Workers | 1 | 2023 | 2 | 0.220 |
Why?
| Geographic Atrophy | 1 | 2023 | 7 | 0.220 |
Why?
| Drainage | 1 | 2023 | 79 | 0.220 |
Why?
| Fibrinolysin | 1 | 2023 | 2 | 0.220 |
Why?
| Cultural Diversity | 1 | 2023 | 39 | 0.220 |
Why?
| Schools, Medical | 1 | 2023 | 70 | 0.220 |
Why?
| Retreatment | 2 | 2014 | 56 | 0.220 |
Why?
| ROC Curve | 1 | 2023 | 232 | 0.220 |
Why?
| Patient Selection | 1 | 2024 | 253 | 0.220 |
Why?
| Faculty, Medical | 1 | 2023 | 92 | 0.210 |
Why?
| Subretinal Fluid | 1 | 2022 | 2 | 0.210 |
Why?
| Vision Screening | 1 | 2022 | 12 | 0.210 |
Why?
| Blood-Retinal Barrier | 1 | 2022 | 6 | 0.210 |
Why?
| Sudan | 1 | 2022 | 2 | 0.210 |
Why?
| Disease Management | 2 | 2021 | 176 | 0.210 |
Why?
| Privacy | 1 | 2022 | 17 | 0.210 |
Why?
| Antibodies, Monoclonal, Humanized | 2 | 2015 | 225 | 0.200 |
Why?
| Cyanoacrylates | 1 | 2021 | 6 | 0.200 |
Why?
| Fibrin Tissue Adhesive | 1 | 2021 | 12 | 0.200 |
Why?
| Recombinant Fusion Proteins | 1 | 2022 | 186 | 0.200 |
Why?
| Prednisone | 1 | 2022 | 101 | 0.200 |
Why?
| Eye Abnormalities | 1 | 2021 | 25 | 0.200 |
Why?
| Vision, Ocular | 1 | 2021 | 11 | 0.200 |
Why?
| Infant | 5 | 2024 | 3563 | 0.200 |
Why?
| Eye | 1 | 2021 | 32 | 0.200 |
Why?
| Ecosystem | 1 | 2022 | 64 | 0.190 |
Why?
| Sensitivity and Specificity | 1 | 2023 | 863 | 0.190 |
Why?
| Prevalence | 3 | 2022 | 951 | 0.190 |
Why?
| Tomography, X-Ray Computed | 2 | 2022 | 1161 | 0.190 |
Why?
| Genome-Wide Association Study | 1 | 2022 | 166 | 0.190 |
Why?
| Diabetes Mellitus, Type 1 | 1 | 2024 | 201 | 0.190 |
Why?
| Disease Outbreaks | 1 | 2022 | 125 | 0.190 |
Why?
| Randomized Controlled Trials as Topic | 1 | 2024 | 550 | 0.190 |
Why?
| Prolapse | 1 | 2020 | 6 | 0.190 |
Why?
| Fungemia | 1 | 2021 | 37 | 0.190 |
Why?
| Electronic Health Records | 3 | 2018 | 213 | 0.190 |
Why?
| Swine | 1 | 2021 | 396 | 0.180 |
Why?
| Oximetry | 2 | 2011 | 67 | 0.180 |
Why?
| Ophthalmoscopy | 1 | 2020 | 14 | 0.180 |
Why?
| Macula Lutea | 1 | 2020 | 3 | 0.180 |
Why?
| Carcinoma, Hepatocellular | 1 | 2022 | 193 | 0.180 |
Why?
| Bacteria | 1 | 2022 | 222 | 0.180 |
Why?
| Retinal Pigment Epithelium | 1 | 2020 | 18 | 0.180 |
Why?
| Blindness | 2 | 2022 | 31 | 0.180 |
Why?
| Algorithms | 1 | 2023 | 618 | 0.180 |
Why?
| Substance Abuse, Intravenous | 1 | 2020 | 43 | 0.170 |
Why?
| Polymorphism, Single Nucleotide | 1 | 2022 | 485 | 0.170 |
Why?
| Fusariosis | 1 | 2019 | 6 | 0.170 |
Why?
| Plant Roots | 1 | 2019 | 33 | 0.170 |
Why?
| Fusarium | 1 | 2019 | 31 | 0.170 |
Why?
| Referral and Consultation | 3 | 2013 | 285 | 0.170 |
Why?
| Quantitative Trait Loci | 1 | 2019 | 42 | 0.160 |
Why?
| Hepatitis C | 1 | 2020 | 79 | 0.160 |
Why?
| Liver Neoplasms | 1 | 2022 | 328 | 0.160 |
Why?
| MicroRNAs | 1 | 2022 | 355 | 0.160 |
Why?
| Water | 1 | 2019 | 75 | 0.160 |
Why?
| Emergencies | 2 | 2009 | 86 | 0.160 |
Why?
| Antibiotic Prophylaxis | 1 | 2019 | 61 | 0.160 |
Why?
| Chromosome Mapping | 1 | 2019 | 156 | 0.160 |
Why?
| Animals | 3 | 2024 | 13246 | 0.160 |
Why?
| Equipment Design | 1 | 2019 | 285 | 0.160 |
Why?
| Alleles | 1 | 2019 | 251 | 0.160 |
Why?
| Gaucher Disease | 1 | 2018 | 16 | 0.160 |
Why?
| Health Literacy | 3 | 2024 | 128 | 0.150 |
Why?
| Surgical Wound Infection | 1 | 2019 | 116 | 0.150 |
Why?
| Recurrence | 2 | 2011 | 662 | 0.150 |
Why?
| Sulfur Hexafluoride | 1 | 2017 | 2 | 0.150 |
Why?
| Treatment Failure | 1 | 2018 | 116 | 0.150 |
Why?
| Drug Therapy, Combination | 2 | 2016 | 381 | 0.150 |
Why?
| Diabetes Mellitus, Type 2 | 1 | 2024 | 486 | 0.150 |
Why?
| Eye Diseases, Hereditary | 1 | 2017 | 5 | 0.150 |
Why?
| Inheritance Patterns | 1 | 2017 | 22 | 0.150 |
Why?
| Fatty Acids | 1 | 2018 | 145 | 0.140 |
Why?
| Penicillins | 1 | 2017 | 28 | 0.140 |
Why?
| Contrast Media | 1 | 2018 | 185 | 0.140 |
Why?
| Time Factors | 3 | 2020 | 2922 | 0.140 |
Why?
| Microsurgery | 2 | 2024 | 30 | 0.130 |
Why?
| Drug Combinations | 1 | 2016 | 126 | 0.130 |
Why?
| Video Recording | 1 | 2016 | 80 | 0.130 |
Why?
| Anesthetics, General | 1 | 2015 | 4 | 0.130 |
Why?
| Visually Impaired Persons | 1 | 2015 | 1 | 0.130 |
Why?
| Dose-Response Relationship, Drug | 2 | 2016 | 1378 | 0.120 |
Why?
| England | 2 | 2012 | 45 | 0.120 |
Why?
| Anesthetics, Local | 1 | 2015 | 75 | 0.120 |
Why?
| Acute Disease | 2 | 2021 | 368 | 0.120 |
Why?
| Microscopy, Acoustic | 1 | 2013 | 5 | 0.120 |
Why?
| Language | 2 | 2024 | 134 | 0.110 |
Why?
| Diagnosis, Differential | 3 | 2017 | 1043 | 0.110 |
Why?
| Glaucoma, Neovascular | 1 | 2012 | 2 | 0.110 |
Why?
| Infusions, Intravenous | 2 | 2017 | 213 | 0.110 |
Why?
| Syndrome | 2 | 2011 | 238 | 0.100 |
Why?
| Risk Assessment | 1 | 2016 | 1262 | 0.100 |
Why?
| Mutation | 1 | 2017 | 1294 | 0.100 |
Why?
| Muscle Hypotonia | 1 | 2011 | 21 | 0.090 |
Why?
| Risperidone | 1 | 2011 | 25 | 0.090 |
Why?
| Eye Hemorrhage | 1 | 2010 | 1 | 0.090 |
Why?
| Cranial Sinuses | 1 | 2010 | 10 | 0.090 |
Why?
| Carotid Artery Injuries | 1 | 2010 | 13 | 0.090 |
Why?
| Arteriovenous Fistula | 1 | 2010 | 22 | 0.090 |
Why?
| Prostaglandins F, Synthetic | 1 | 2009 | 1 | 0.080 |
Why?
| Anti-Inflammatory Agents | 1 | 2011 | 160 | 0.080 |
Why?
| Prednisolone | 1 | 2009 | 55 | 0.080 |
Why?
| Carbonic Anhydrase Inhibitors | 1 | 2008 | 5 | 0.080 |
Why?
| Antipsychotic Agents | 1 | 2011 | 232 | 0.080 |
Why?
| Acetazolamide | 1 | 2008 | 18 | 0.080 |
Why?
| Oxygen | 1 | 2011 | 325 | 0.080 |
Why?
| Pupil | 1 | 2008 | 30 | 0.080 |
Why?
| Vitreous Hemorrhage | 1 | 2008 | 5 | 0.080 |
Why?
| Prostatic Hyperplasia | 1 | 2008 | 39 | 0.080 |
Why?
| Mass Screening | 1 | 2011 | 346 | 0.080 |
Why?
| Injections | 1 | 2008 | 56 | 0.080 |
Why?
| Electroretinography | 2 | 2018 | 15 | 0.080 |
Why?
| Cefuroxime | 1 | 2007 | 3 | 0.080 |
Why?
| Models, Biological | 1 | 2011 | 723 | 0.080 |
Why?
| Cefazolin | 1 | 2007 | 12 | 0.070 |
Why?
| Capsulorhexis | 1 | 2007 | 1 | 0.070 |
Why?
| Rupture | 1 | 2007 | 24 | 0.070 |
Why?
| Astigmatism | 1 | 2007 | 5 | 0.070 |
Why?
| Neoplasm Metastasis | 1 | 2007 | 236 | 0.070 |
Why?
| Chronic Disease | 1 | 2009 | 571 | 0.070 |
Why?
| Clinical Competence | 1 | 2008 | 392 | 0.060 |
Why?
| Reagins | 1 | 2024 | 2 | 0.060 |
Why?
| Posterior Eye Segment | 1 | 2024 | 2 | 0.060 |
Why?
| Sex Distribution | 1 | 2024 | 133 | 0.060 |
Why?
| Prosthesis Implantation | 1 | 2024 | 46 | 0.060 |
Why?
| Antibodies, Bacterial | 1 | 2024 | 28 | 0.060 |
Why?
| Rumen | 1 | 2024 | 1 | 0.060 |
Why?
| Tannins | 1 | 2024 | 3 | 0.060 |
Why?
| Fermentation | 1 | 2024 | 8 | 0.060 |
Why?
| Goats | 1 | 2024 | 11 | 0.060 |
Why?
| Diplopia | 1 | 2024 | 20 | 0.060 |
Why?
| Teaching Materials | 1 | 2024 | 31 | 0.060 |
Why?
| Animal Feed | 1 | 2024 | 56 | 0.060 |
Why?
| Reading | 1 | 2024 | 83 | 0.060 |
Why?
| Antifungal Agents | 1 | 2006 | 339 | 0.060 |
Why?
| Immunoglobulin G | 1 | 2024 | 186 | 0.060 |
Why?
| Anesthesia | 1 | 2024 | 73 | 0.060 |
Why?
| Homosexuality, Male | 1 | 2023 | 51 | 0.050 |
Why?
| Surgical Flaps | 1 | 2024 | 120 | 0.050 |
Why?
| Retinal Ganglion Cells | 1 | 2022 | 13 | 0.050 |
Why?
| Traction | 1 | 2021 | 7 | 0.050 |
Why?
| Reoperation | 2 | 2014 | 454 | 0.050 |
Why?
| Socioeconomic Factors | 1 | 2023 | 579 | 0.050 |
Why?
| Health Status Disparities | 1 | 2023 | 194 | 0.050 |
Why?
| Atrophy | 1 | 2020 | 38 | 0.040 |
Why?
| Diet | 1 | 2024 | 557 | 0.040 |
Why?
| Emergency Service, Hospital | 1 | 2024 | 484 | 0.040 |
Why?
| Healthcare Disparities | 1 | 2023 | 268 | 0.040 |
Why?
| Europe | 1 | 2019 | 76 | 0.040 |
Why?
| Pandemics | 1 | 2024 | 562 | 0.040 |
Why?
| Gene Expression Regulation, Neoplastic | 1 | 2022 | 828 | 0.040 |
Why?
| Administration, Oral | 2 | 2011 | 434 | 0.040 |
Why?
| Glucosylceramidase | 1 | 2018 | 9 | 0.040 |
Why?
| Enzyme Replacement Therapy | 1 | 2018 | 17 | 0.040 |
Why?
| Visual Fields | 1 | 2018 | 37 | 0.040 |
Why?
| Transplantation, Autologous | 1 | 2020 | 469 | 0.040 |
Why?
| Prone Position | 1 | 2017 | 31 | 0.040 |
Why?
| Genes, Recessive | 1 | 2017 | 16 | 0.040 |
Why?
| Consanguinity | 1 | 2017 | 18 | 0.040 |
Why?
| Heterozygote | 1 | 2017 | 81 | 0.040 |
Why?
| Pedigree | 1 | 2017 | 125 | 0.040 |
Why?
| DNA Mutational Analysis | 1 | 2017 | 176 | 0.030 |
Why?
| Recombinant Proteins | 1 | 2018 | 487 | 0.030 |
Why?
| Genetic Association Studies | 1 | 2017 | 116 | 0.030 |
Why?
| Genetic Testing | 1 | 2017 | 119 | 0.030 |
Why?
| Rupture, Spontaneous | 1 | 2016 | 20 | 0.030 |
Why?
| Practice Guidelines as Topic | 1 | 2019 | 449 | 0.030 |
Why?
| Pregnancy | 1 | 2023 | 2604 | 0.030 |
Why?
| Survival Analysis | 1 | 2016 | 666 | 0.030 |
Why?
| Gonioscopy | 1 | 2012 | 3 | 0.030 |
Why?
| Age Distribution | 1 | 2013 | 168 | 0.030 |
Why?
| Choroidal Neovascularization | 1 | 2013 | 54 | 0.030 |
Why?
| Neovascularization, Pathologic | 1 | 2012 | 162 | 0.020 |
Why?
| Retinal Artery | 1 | 2011 | 4 | 0.020 |
Why?
| Coloring Agents | 1 | 2011 | 70 | 0.020 |
Why?
| Serotonin 5-HT2 Receptor Antagonists | 1 | 2011 | 9 | 0.020 |
Why?
| Indocyanine Green | 1 | 2011 | 34 | 0.020 |
Why?
| Dopamine Antagonists | 1 | 2011 | 21 | 0.020 |
Why?
| Angiography | 1 | 2011 | 130 | 0.020 |
Why?
| Injections, Intraocular | 1 | 2010 | 6 | 0.020 |
Why?
| Regional Blood Flow | 1 | 2011 | 108 | 0.020 |
Why?
| Methylprednisolone | 1 | 2010 | 38 | 0.020 |
Why?
| Orbit | 1 | 2010 | 29 | 0.020 |
Why?
| Chemotherapy, Adjuvant | 1 | 2011 | 120 | 0.020 |
Why?
| Adrenal Cortex Hormones | 1 | 2011 | 94 | 0.020 |
Why?
| Schizophrenia | 1 | 2011 | 256 | 0.020 |
Why?
| Immunosuppressive Agents | 1 | 2011 | 222 | 0.020 |
Why?
| Sweden | 1 | 2007 | 9 | 0.020 |
Why?
|
|
Sallam's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|